Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 7/20 | 0.57 |
| ▸ | RXRB | P28702 | 4/20 | 0.57 |
| ▸ | RXRG | P48443 | 4/20 | 0.57 |
| ▸ | CYP26B1 | Q9NR63 | 8/20 | 0.54 |
| ▸ | CYP26A1 | O43174 | 7/20 | 0.54 |
| ▸ | RARB | P10826 | 4/20 | 0.48 |
| ▸ | RARG | P13631 | 4/20 | 0.48 |
| ▸ | RARA | P10276 | 3/20 | 0.48 |
| ▸ | PPARG | P37231 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4365965 | 0.85 | CYP26B1 (0.55) | RXRARXRBRXRGCYP26B1CYP26A1 | |
| SCHEMBL9507898 | 0.84 | PPARG (0.50) | RXRARXRBRXRGCYP26B1CYP26A1 | |
| SCHEMBL10834477 | 0.84 | RARB (0.59) | RXRARXRBRXRGCYP26B1CYP26A1 | |
| SCHEMBL10339561 | 0.82 | ESR1 (0.41) | RXRARXRBRXRGCYP26B1CYP26A1 | |
| SCHEMBL4668411 | 0.82 | CYP26B1 (0.52) | RXRARXRBRXRGCYP26B1CYP26A1 | |
| SCHEMBL3176733 | 0.82 | RXRA (0.54) | RXRARXRBRXRGCYP26B1CYP26A1 | |
| SCHEMBL9484092 | 0.81 | RARB (0.62) | RXRARXRBRXRGCYP26B1CYP26A1 | |
| SCHEMBL7751241 | 0.81 | CYP26A1 (0.48) | RXRARXRBRXRGCYP26B1CYP26A1 | |
| SCHEMBL12491381 | 0.81 | ESR2 (0.47) | RXRARXRBRXRGCYP26B1CYP26A1 | |
| SCHEMBL8677714 | 0.80 | PPARG (0.53) | RXRARXRBRXRGCYP26B1CYP26A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020154431-A1 | INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY | LYNCH KEVIN R (US) | 2020-07-30 | — | — | WO | disclosed |
| EP-2358656-B1 | SPIROCYCLIC GPR40 MODULATORS | AMGEN INC (US) | 2014-01-01 | — | — | EP | disclosed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| EP-1692097-B1 | TRICYCLIC HYDROXAMATE AND BENZAMIDE DERIVATIVES, COMPOSITIONS AND METHODS | EXONHIT THERAPEUTICS SA (FR) | 2009-09-02 | — | — | EP | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| US-5688817-A | SKIN DISORDERS, ANTIINFLAMMATORY AGENTS, IMMUNOLOGY AND RHEUMATIC DISORDERS | CENTRE INT'L. DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 1997-11-18 | — | — | US | disclosed |
| US-5668156-A | TREATMENT OF WARTS, ACNE, PSORIASIS, CORNEOPATHIES, KETONES | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1997-09-16 | — | — | US | disclosed |
| US-5597839-A | TREATMENT OF SKIN DISORDERS OR ANTIINFLAMMATORY AGENTS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1997-01-28 | — | — | US | disclosed |
| US-5567721-A | AROMATIC UREA COMPOUND FOR SKIN DISORDER, RHEUMATIC DISEASE, RESPIRATORY DISORDER AND EYE DISORDER | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES (FR) | 1996-10-22 | — | — | US | disclosed |
| US-5439925-A | Skin disorders, rheumatic diseases | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1995-08-08 | — | — | US | disclosed |
| US-5387594-A | Administering for topical and systemic treatment of | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1995-02-07 | — | — | US | disclosed |
| EP-0552282-B1 | BI-AROMATIC COMPOUNDS AND THEIR USE IN HUMAN AND VETERINARY MEDECINE AND IN COSMETIC PREPARATIONS | CIRD GALDERMA (FR) | 1994-08-24 | — | — | EP | disclosed |
| EP-0552282-A1 | BI-AROMATIC COMPOUNDS AND THEIR USE IN HUMAN AND VETERINARY MEDECINE AND IN COSMETIC PREPARATIONS. | CIRD GALDERMA (FR) | 1993-07-28 | — | — | EP | disclosed |
| WO-1992006948-A1 | BI-AROMATIC COMPOUNDS AND THEIR USE IN HUMAN AND VETERINARY MEDECINE AND IN COSMETIC PREPARATIONS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1992-04-30 | — | — | WO | disclosed |
| US-4833240-A | SKIN DISORDERS; ANTIINFLAMMATORY AGENTS; ANTIALLLERGENS; ANTITUMOR AGENTS; OPHTHALMOLOGY | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES (CIRD) (FR) | 1989-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | RXRA 179/4885RXRB 138/4885RXRG 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.